Literature DB >> 4014224

Tartrate-resistant acid phosphatase staining of monocytes in Gaucher disease.

K Troy, J Cuttner, M Reilly, G Grabowski, R Desnick.   

Abstract

Cytochemical studies were performed on peripheral blood from 30 patients with type 1 Gaucher disease. In 29 of the patients, peripheral blood monocytes stained positively for tartrate-resistant acid phosphatase, whereas monocytes from 18 normal individuals and 14 patients with monocytosis did not. In the Gaucher patients, the percentage of monocyte positivity for tartrate-resistant acid phosphatase ranged from 2 to 97. There was no correlation between the percent monocyte staining and the degree of disease severity, as measured by hepatosplenomegaly, pancytopenia, or extent of bone disease, for the group as a whole. In Gaucher patients who had not undergone splenectomy, however, there was a significant correlation between percent monocyte staining and the degree of hepatosplenomegaly, anemia, and thrombocytopenia. The presence of tartrate-resistant acid phosphatase may be secondary to the lysosomal accumulation of glucosyl ceramide within these monocytes, although this remains to be confirmed. If so, these circulating cells may represent precursors of the Gaucher cells in tissues. Tartrate-resistant acid phosphatase staining of peripheral blood monocytes may be useful as a diagnostic marker for Gaucher type 1 disease and for further studies on the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4014224     DOI: 10.1002/ajh.2830190305

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  Immunohistochemical characterization of purple acid phosphatase-containing leucocytes in the human placenta.

Authors:  J Schindelmeiser; D Münstermann
Journal:  Histochem J       Date:  1991-01

2.  Histochemical investigations on the localization of the purple acid phosphatase in the bovine spleen.

Authors:  J Schindelmeiser; D Münstermann; H Witzel
Journal:  Histochemistry       Date:  1987

Review 3.  Impotence: diagnosis and management of male erectile dysfunction.

Authors:  R S Kirby
Journal:  BMJ       Date:  1994-04-09

4.  Bone events and evolution of biologic markers in Gaucher disease before and during treatment.

Authors:  Jérôme Stirnemann; Nadia Belmatoug; Corine Vincent; Olivier Fain; Bruno Fantin; France Mentré
Journal:  Arthritis Res Ther       Date:  2010-08-09       Impact factor: 5.156

5.  Human innate immune responses to hexamethylene diisocyanate (HDI) and HDI-albumin conjugates.

Authors:  A V Wisnewski; Q Liu; J Liu; C A Redlich
Journal:  Clin Exp Allergy       Date:  2008-06       Impact factor: 5.018

6.  Transcriptional regulation of the tartrate-resistant acid phosphatase (TRAP) gene by iron.

Authors:  O Alcantara; S V Reddy; G D Roodman; D H Boldt
Journal:  Biochem J       Date:  1994-03-01       Impact factor: 3.857

7.  The Effect of Osteoblast Isolation Methods from Adult Rats on Osteoclastogenesis in Co-Cultures.

Authors:  Radmila Žižková; Věra Hedvičáková; Veronika Hefka Blahnová; Věra Sovková; Michala Rampichová; Eva Filová
Journal:  Int J Mol Sci       Date:  2022-07-17       Impact factor: 6.208

8.  TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease.

Authors:  Margarita Ivanova; Julia Dao; Lauren Noll; Jacqueline Fikry; Ozlem Goker-Alpan
Journal:  J Clin Med       Date:  2021-05-20       Impact factor: 4.241

9.  The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients.

Authors:  Jérôme Stirnemann; Marie Vigan; Dalil Hamroun; Djazia Heraoui; Linda Rossi-Semerano; Marc G Berger; Christian Rose; Fabrice Camou; Christine de Roux-Serratrice; Bernard Grosbois; Pierre Kaminsky; Alain Robert; Catherine Caillaud; Roselyne Froissart; Thierry Levade; Agathe Masseau; Cyril Mignot; Frédéric Sedel; Dries Dobbelaere; Marie T Vanier; Vassili Valayanopoulos; Olivier Fain; Bruno Fantin; Thierry Billette de Villemeur; France Mentré; Nadia Belmatoug
Journal:  Orphanet J Rare Dis       Date:  2012-10-09       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.